NASDAQ:PRXL - PAREXEL International Stock Price, Price Target & More

$88.08 -0.02 (-0.02 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$88.10

Today's Range$88.07 - $88.10

52-Week Range$51.16 - $88.10

Volume7.02 million shs

Average Volume1.04 million shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

About PAREXEL International (NASDAQ:PRXL)

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company's PI segment provides information technology solutions.

Receive PRXL News and Ratings via Email

Sign-up to receive the latest news and ratings for PRXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A

Sub-IndustryLife Sciences Tools & Services

SectorN/A

SymbolNASDAQ:PRXL

CUSIP69946210

Webwww.parexel.com

Phone+1-781-4879900

Debt

Debt-to-Equity Ratio1.01%

Current Ratio1.45%

Quick Ratio1.45%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins4.62%

Return on Equity19.95%

Return on Assets5.29%

Miscellaneous

Employees18,900

Outstanding Shares51,120,000

How to Become a New Pot Stock Millionaire

PAREXEL International (NASDAQ:PRXL) Frequently Asked Questions

What is PAREXEL International's stock symbol?

PAREXEL International trades on the NASDAQ under the ticker symbol "PRXL."

How were PAREXEL International's earnings last quarter?

PAREXEL International Co. (NASDAQ:PRXL) released its quarterly earnings results on Wednesday, October, 26th. The medical research company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.86 by $0.10. The medical research company had revenue of $500.90 million for the quarter, compared to analyst estimates of $525.15 million. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The firm's revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter last year, the company earned $0.70 EPS. View PAREXEL International's Earnings History.

What price target have analysts set for PRXL?

6 Wall Street analysts have issued 1-year target prices for PAREXEL International's shares. Their forecasts range from $75.00 to $88.10. On average, they anticipate PAREXEL International's share price to reach $82.5167 in the next twelve months. View Analyst Ratings for PAREXEL International.

Who are PAREXEL International's key executives?

PAREXEL International's management team includes the folowing people:

Josef H. von Rickenbach, Chairman of the Board, Chief Executive Officer
Mark A. Goldberg M.D., President, Chief Operating Officer
Simon Harford, Chief Financial Officer, Senior Vice President
, Bio & Compensation -
Xavier AB Flinois, President - PAREXEL Informatics
Michelle Graham, Chief Human Resource Officer, Senior Vice President
Sybrand Pretorius M.D., Senior Vice President, Chief Scientific Officer
Douglas Alexander Batt, Senior Vice President, General Counsel, Secretary
Roland Andersson Ph.d., Senior Vice President - Clinical Research Services
Christian Dreger Ph.D., Senior Vice President - Parexel Access and Parexel Consulting
, Bio & Compensation -
David J. Godwin, Senior Vice President-Global Business

Has PAREXEL International been receiving favorable news coverage?

News stories about PRXL stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PAREXEL International earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 46.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of PAREXEL International?

Shares of PRXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PAREXEL International's stock price today?

One share of PRXL stock can currently be purchased for approximately $88.08.

How can I contact PAREXEL International?

PAREXEL International's mailing address is 195 West St, WALTHAM, MA 02451-1111, United States. The medical research company can be reached via phone at +1-781-4879900.

MarketBeat Community Rating for PAREXEL International (PRXL)

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		302 (Vote Outperform)
Underperform Votes:		413 (Vote Underperform)
Total Votes:		715

MarketBeat's community ratings are surveys of what our community members think about PAREXEL International and other stocks. Vote "Outperform" if you believe PRXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRXL will underperform the S&P 500 over the long term. You may vote once every thirty days.

PAREXEL International (NASDAQ:PRXL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for PAREXEL International in the last 12 months. Their average twelve-month price target is $82.5167, suggesting that the stock has a possible downside of 6.32%. The high price target for PRXL is $88.10 and the low price target for PRXL is $75.00. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.33	2.33	1.90	1.93
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 5 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 9 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$82.5167	$82.5167	$78.30	$73.71
Price Target Upside:	6.32% downside	5.43% downside	10.26% downside	15.52% downside

PAREXEL International (NASDAQ:PRXL) Consensus Price Target History

Price Target History for PAREXEL International (NASDAQ:PRXL)

PAREXEL International (NASDAQ:PRXL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/21/2017	Jefferies Group	Reiterated Rating	Hold	$88.10	Low
6/20/2017	Barclays	Downgrade	Overweighr -> Equal Weight	$87.00	High
6/20/2017	Raymond James	Upgrade	Underperform -> Mkt Perform		High
6/6/2017	Credit Suisse Group	Reiterated Rating	Neutral	$65.00 -> $83.00	Low
5/30/2017	Mizuho	Boost Price Target	Buy -> Buy	$66.00 -> $75.00	Low
5/23/2017	Goldman Sachs	Upgrade	Sell -> Neutral	$63.00 -> $77.00	Low
5/15/2017	Evercore ISI	Upgrade	In-Line -> Outperform	$85.00	Low
2/3/2017	Deutsche Bank	Downgrade	Hold -> Sell	$66.00 -> $53.00	N/A
2/3/2017	Citigroup	Downgrade	Buy -> Neutral		N/A
2/2/2017	UBS	Downgrade	Market Perform -> Underperform		N/A
11/23/2016	Wells Fargo	Downgrade	Outperform -> Market Perform		N/A
11/17/2016	First Analysis	Downgrade	Overweight -> Equal Weight	$62.00	N/A
11/11/2016	SunTrust Banks	Downgrade	Buy -> Hold	$80.00 -> $60.00	N/A
10/27/2016	Robert W. Baird	Downgrade	Outperform -> Neutral	$78.00 -> $67.00	N/A
7/18/2016	William Blair	Downgrade	Outperform -> Market Perform		N/A
5/22/2016	KeyCorp	Reiterated Rating	Hold		N/A

(Data available from 4/25/2016 forward)

PAREXEL International (NASDAQ:PRXL) Earnings History and Estimates Chart

Earnings by Quarter for PAREXEL International (NASDAQ:PRXL)

PAREXEL International (NASDAQ:PRXL) Earnings Estimates

2018 EPS Consensus Estimate: $3.86

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$0.85	$0.94	$0.88
Q2 2018	5	$0.93	$0.99	$0.96
Q3 2018	5	$0.94	$0.98	$0.97
Q4 2018	4	$1.04	$1.10	$1.06

PAREXEL International (NASDAQ PRXL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/28/2017	Q4 2017	$0.94	$1.02	$537.59 million	$557.20 million	View	N/A
5/3/2017	Q3 2017	$0.73	$0.74	$529.38 million	$529.30 million	View	Listen
2/1/2017	Q2 2017	$0.83	$0.85	$537.37 million	$534.40 million	View	N/A
10/26/2016	Q117	$0.86	$0.76	$525.15 million	$500.90 million	View	Listen
8/3/2016	Q416	$0.93	$0.94	$532.41 million	$538.60 million	View	Listen
4/27/2016	Q316	$0.90	$0.89	$523.16 million	$527.10 million	View	Listen
1/27/2016	Q2	$0.72	$0.90	$523.03 million	$518.50 million	View	Listen
10/28/2015	Q116	$0.63	$0.70	$511.77 million	$512.10 million	View	Listen
8/5/2015	Q415	$0.74	$0.79	$527.13 million	$523.00 million	View	Listen
4/29/2015	Q315	$0.66	$0.66	$513.50 million	$502.03 million	View	Listen
1/28/2015	Q215	$0.60	$0.69	$502.20 million	$499.27 million	View	Listen
10/30/2014	Q115	$0.58	$0.65	$505.60 million	$491.69 million	View	Listen
8/7/2014	Q414	$0.62	$0.65	$508.99 million	$510.60 million	View	Listen
4/29/2014	Q314	$0.54	$0.56	$493.35 million	$492.40 million	View	Listen
1/30/2014	Q214	$0.49	$0.49	$479.49 million	$487.10 million	View	Listen
10/30/2013	Q114	$0.45	$0.45	$458.94 million	$449.20 million	View	Listen
8/7/2013	Q4 2013	$0.43	$0.50	$455.23 million	$463.10 million	View	Listen
4/30/2013	Q3 2013	$0.40	$0.50	$438.10 million	$454.49 million	View	Listen
1/29/2013	Q2 2013	$0.33	$0.41	$419.78 million	$422.10 million	View	Listen
10/30/2012	Q113	$0.29	$0.29	$396.70 million	$394.80 million	View	N/A
8/8/2012	Q4 2012	$0.29	$0.34			View	N/A
4/30/2012		$0.31	$0.33			View	N/A
1/30/2012		$0.23	$0.23			View	N/A
10/31/2011		$0.15	$0.20			View	N/A
8/9/2011		$0.07	$0.10			View	N/A
5/2/2011		$0.30	$0.27			View	N/A
1/31/2011		$0.28	$0.28			View	N/A
11/1/2010	Q1 2011	$0.28	$0.30			View	N/A
8/9/2010	Q4 2010	$0.30	$0.32			View	N/A
4/27/2010	Q3 2010	$0.27	$0.28			View	N/A
1/25/2010	Q2 2010	$0.22	$0.26			View	N/A
10/27/2009	Q1 2010	$0.17	$0.21			View	N/A
8/10/2009	Q4 2009	$0.27	$0.11			View	N/A
4/27/2009	Q3 2009	$0.23	$0.25			View	N/A
1/26/2009	Q2 2009	$0.20	$0.23			View	N/A
10/27/2008	Q1 2009	$0.22	$0.23			View	N/A
8/6/2008	Q4 2008	$0.26	$0.28			View	N/A
4/23/2008	Q3 2008	$0.22	$0.24			View	N/A
1/23/2008	Q2 2008	$0.20	$0.20			View	N/A

(Earnings results data provided by Zacks Investment Research)

PAREXEL International (NASDAQ:PRXL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

PAREXEL International (NASDAQ PRXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 87.45%

Insider Trading History for PAREXEL International (NASDAQ:PRXL)

PAREXEL International (NASDAQ PRXL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2017	Sybrand Pretorius	SVP	Sell	8,050	$65.12	$524,216.00	9,950
2/9/2017	Gadi Saarony	Insider	Sell	2,325	$64.54	$150,055.50	14,208
8/15/2016	Gadi Saarony	Insider	Sell	2,500	$70.05	$175,125.00	9,417
8/9/2016	Joshua Schultz	SVP	Sell	2,500	$68.64	$171,600.00	5,168
6/13/2016	A Dana Callow Jr	Director	Sell	3,000	$60.04	$180,120.00	34,072
6/2/2016	Eduard E Holdener	Director	Sell	700	$62.98	$44,086.00	12,471
5/25/2016	Ulf I Schneider	SVP	Sell	7,500	$62.00	$465,000.00	35,030
5/24/2016	Ulf I Schneider	SVP	Sell	6,000	$61.00	$366,000.00	33,530
5/23/2016	Ulf I Schneider	SVP	Sell	6,000	$60.01	$360,060.00	33,530
5/20/2016	Ulf I Schneider	SVP	Sell	8,000	$59.24	$473,920.00	35,530
3/30/2016	Richard L Love	Director	Sell	1,330	$62.50	$83,125.00	84,110
12/1/2015	Richard L Love	Director	Sell	1,330	$68.21	$90,719.30	85,440
11/24/2015	Eduard E Holdener	Director	Sell	2,200	$67.66	$148,852.00	13,171
11/12/2015	Gadi Saarony	SVP	Sell	12,425	$67.01	$832,599.25	11,917
11/11/2015	Patrick J Fortune	Director	Sell	1,500	$68.07	$102,105.00	24,653
9/1/2015	Richard L Love	Director	Sell	1,330	$64.26	$85,465.80	84,350
8/18/2015	Mark A Goldberg	COO	Sell	8,995	$73.49	$661,042.55
8/18/2015	Thomas Senderovitz	SVP	Sell	1,500	$74.02	$111,030.00
6/18/2015	Mark A Goldberg	COO	Sell	11,507	$70.03	$805,835.21
5/14/2015	Richard L Love	Director	Sell	5,000	$65.00	$325,000.00
3/19/2015	Mark A Goldberg	COO	Sell	12,884	$68.99	$888,867.16
3/2/2015	A Dana Callow Jr	Director	Sell	2,000	$65.84	$131,680.00
2/19/2015	Christopher J Lindop	Director	Sell	2,000	$63.59	$127,180.00
2/13/2015	Rickenbach Josef H Von	CEO	Sell	65,100	$62.53	$4,070,703.00
2/6/2015	Eduard E Holdener	Director	Sell	3,000	$62.97	$188,910.00
2/4/2015	Douglas A Batt	SVP	Sell	8,300	$60.89	$505,387.00
2/3/2015	Gadi Saarony	VP	Sell	8,525	$60.97	$519,769.25
12/3/2014	Mark A Goldberg	COO	Sell	25,345	$58.99	$1,495,101.55
11/5/2014	Christopher J Lindop	Director	Sell	12,000	$55.00	$660,000.00
8/20/2014	Gadi Saarony	VP	Sell	6,075	$57.78	$351,013.50
8/18/2014	Anita Cooper	VP	Sell	4,916	$57.56	$282,964.96
8/15/2014	Anita Cooper	VP	Sell	5,084	$57.50	$292,330.00
8/14/2014	Anita Cooper	VP	Sell	6,800	$57.54	$391,272.00
8/13/2014	Mark A Goldberg	COO	Sell	16,761	$56.33	$944,147.13
8/11/2014	Richard L Love	Director	Sell	6,000	$57.33	$343,980.00
6/5/2014	Patrick J Fortune	Director	Sell	3,000	$53.04	$159,120.00
2/20/2014	Anita Cooper	VP	Sell	2,500	$53.00	$132,500.00	23,286
2/18/2014	Mark Goldberg	COO	Sell	11,206	$52.49	$588,202.94	105,088
2/12/2014	Mark Goldberg	COO	Sell	12,199	$50.49	$615,927.51	105,088
2/11/2014	Anita Cooper	VP	Sell	10,000	$50.00	$500,000.00	23,286
2/10/2014	Eduard Holdener	Director	Sell	6,000	$49.62	$297,720.00	13,289
2/10/2014	Rickenbach Josef Von	CEO	Sell	50,000	$49.76	$2,488,000.00	562,641
2/7/2014	Gadi Saarony	VP	Sell	9,950	$49.56	$493,122.00	8,700
2/7/2014	Rickenbach Josef Von	CEO	Sell	50,000	$49.70	$2,485,000.00	612,641
2/4/2014	Christopher Lindop	Director	Sell	10,000	$49.00	$490,000.00	29,593
2/3/2014	Douglas Batt	SVP	Sell	8,000	$48.58	$388,640.00	60,457
2/3/2014	Mark Goldberg	COO	Sell	13,529	$48.70	$658,862.30	105,088
1/13/2014	Mark Goldberg	COO	Sell	6,957	$48.90	$340,197.30	118,617
1/9/2014	Mark Goldberg	COO	Sell	6,901	$46.49	$320,827.49	118,617
12/12/2013	Xavier Flinois	Insider	Buy	5,000	$41.11	$205,550.00	11,800
9/11/2013	Patrick Fortune	Director	Sell	7,000	$48.31	$338,170.00	22,182
8/28/2013	Richard Love	Director	Sell	5,000	$47.04	$235,200.00	90,741
6/4/2013	Douglas A Batt	SVP	Sell	15,000	$45.15	$677,250.00
6/3/2013	Mark A Goldberg	COO	Sell	15,000	$45.06	$675,900.00
5/20/2013	Richard L Love	Director	Sell	8,000	$46.65	$373,200.00
5/14/2013	A Dana Callow Jr	Director	Sell	8,000	$46.39	$371,120.00
5/13/2013	Mark A Goldberg	COO	Sell	28,887	$45.19	$1,305,403.53
5/10/2013	Anita Cooper	VP	Sell	10,000	$44.99	$449,900.00
5/9/2013	Ulf I Schneider	SVP	Sell	20,510	$44.54	$913,515.40
10/4/2012	Mark A Goldberg	COO	Sell	5,000	$32.00	$160,000.00

(Data available from 1/1/2013 forward)

PAREXEL International (NASDAQ PRXL) News Headlines

Source:

Date	Headline
	PAREXEL International (PRXL) Lifted to "Mkt Perform" at Raymond James www.americanbankingnews.com - April 20 at 8:00 PM
	PAREXEL International (PRXL) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 9 at 4:41 PM
	Analyzing PAREXEL International (PRXL) & Celator Pharmaceuticals (CPXX) www.americanbankingnews.com - March 19 at 9:29 AM
	Comparing Alkermes (ALKS) and PAREXEL International (PRXL) www.americanbankingnews.com - January 27 at 3:32 AM
	Reviewing PAREXEL International (PRXL) & Crispr Therapeutics (CRSP) www.americanbankingnews.com - December 15 at 8:45 AM
	PAREXEL Launches Perceptive® Cloud for the Life Sciences Industry finance.yahoo.com - December 12 at 10:50 AM
	PAREXEL International Co. (PRXL) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - November 27 at 4:28 PM
	Head to Head Review: Senomyx (SNMX) & PAREXEL International (PRXL) www.americanbankingnews.com - November 19 at 11:34 AM
	PAREXEL Expands Global Regulatory Services with Addition of Senior Executives from FDA and Oncology Industry finance.yahoo.com - November 18 at 11:02 AM
	PAREXEL International (PRXL) vs. INC Research Holdings (INCR) Critical Survey www.americanbankingnews.com - November 5 at 7:16 PM
	Reviewing PAREXEL International (PRXL) & Its Competitors www.americanbankingnews.com - November 3 at 5:32 AM
	PAREXEL International Co. (PRXL) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - November 2 at 5:48 PM
	Analyzing PAREXEL International Corporation (PRXL) and Its Rivals www.americanbankingnews.com - October 17 at 12:54 PM
	PAREXEL International Corporation (PRXL) to Release Earnings on Tuesday www.americanbankingnews.com - October 17 at 6:26 AM
	PAREXEL International Corporation (PRXL) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - October 8 at 2:44 PM
	Pamplona Capital Management Completes Acquisition of PAREXEL International www.marketwatch.com - September 29 at 6:18 PM
	Six Flags Entertainment and Sterling Bancorp Set to Join S&P MidCap 400; Oil States Intl. and KEMET to Join S&P SmallCap 600 finance.yahoo.com - September 26 at 7:05 PM
	PAREXEL International Corporation (PRXL) & Exact Sciences Corporation (EXAS) Financial Comparison www.americanbankingnews.com - September 24 at 12:20 AM
	PAREXEL International Receives Shareholder Approval for Proposed Acquisition by Pamplona Capital Management finance.yahoo.com - September 19 at 6:44 AM
	$538.12 Million in Sales Expected for PAREXEL International Corporation (PRXL) This Quarter www.americanbankingnews.com - September 14 at 10:05 AM
	PAREXEL International Corporation (PRXL) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - September 13 at 4:46 PM
	ETFs with exposure to PAREXEL International Corp. : September 7, 2017 finance.yahoo.com - September 8 at 7:17 AM
	PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments finance.yahoo.com - September 7 at 7:52 AM
	PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments finance.yahoo.com - September 7 at 7:52 AM
	PAREXEL International Corp. :PRXL-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017 finance.yahoo.com - September 2 at 7:43 AM
	Brokers Issue Forecasts for PAREXEL International Corporation's Q1 2018 Earnings (PRXL) www.americanbankingnews.com - August 31 at 10:39 AM
	After-Hours Earnings Report for August 28, 2017 : PRXL, CTLT, PSEC, AMSWA, EXA, PRCP - Nasdaq www.nasdaq.com - August 29 at 6:54 AM
	Parexel beats Street 4Q forecasts - Yahoo Finance - Yahoo Finance finance.yahoo.com - August 29 at 6:54 AM
	Parexel beats Street 4Q forecasts finance.yahoo.com - August 29 at 6:54 AM
	PAREXEL International Corporation (PRXL) Posts Earnings Results, Beats Expectations By $0.09 EPS www.americanbankingnews.com - August 28 at 8:22 PM
	PAREXEL International Corporation (PRXL) Short Interest Update www.americanbankingnews.com - August 28 at 1:48 AM
	PAREXEL International Corporation (PRXL) Expected to Announce Quarterly Sales of $537.57 Million www.americanbankingnews.com - August 26 at 11:52 AM
	Analysts Anticipate PAREXEL International Corporation (PRXL) to Post $0.94 EPS www.americanbankingnews.com - August 24 at 2:10 PM
	PAREXEL Ties Up With Osaka International Cancer Institute finance.yahoo.com - August 22 at 4:02 PM
	PAREXEL International Corporation (PRXL) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - August 22 at 10:30 AM
	PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan finance.yahoo.com - August 22 at 6:03 AM
	PAREXEL and Osaka International Cancer Institute Form Alliance to Advance Clinical Research in Japan finance.yahoo.com - August 22 at 6:03 AM
	SHAREHOLDER ALERT: Rigrodsky & Long, PA Files Class Action Suit Against PAREXEL International Corporation - GlobeNewswire (press release) globenewswire.com - August 17 at 3:22 PM
	SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of PAREXEL International ... - PR Newswire (press release) www.prnewswire.com - August 17 at 3:22 PM
	SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against PAREXEL International Corporation feeds.benzinga.com - August 15 at 9:28 PM
	SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of PAREXEL International Corporation - PRXL finance.yahoo.com - August 15 at 6:25 AM
	Novavax (NVAX) & PAREXEL International Corporation (PRXL) Financial Analysis www.americanbankingnews.com - August 14 at 8:42 AM
	Short Interest in PAREXEL International Corporation (NASDAQ:PRXL) Declines By 30.5% www.americanbankingnews.com - August 14 at 2:14 AM
	See what the IHS Markit Score report has to say about PAREXEL International Corp. finance.yahoo.com - August 13 at 4:07 AM
	IHS Markit Score Update: Drop in demand for ETFs holding PAREXEL International Corp is a negative sign for its shares finance.yahoo.com - August 11 at 7:45 AM
	PAREXEL International Corporation -- Moody's assigns a B2 CFR to PAREXEL; outlook stable finance.yahoo.com - August 9 at 6:34 AM
	PAREXEL International Corporation Announces $720 Million Senior Notes Offering by West Street Merger Sub, Inc. finance.yahoo.com - August 8 at 6:21 AM
	Two PAREXEL Executives Named to 2017 PharmaVOICE 100 finance.yahoo.com - August 2 at 6:50 AM
	PAREXEL International Corporation (PRXL) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - July 25 at 4:51 PM
	Stock Performance Review on Medical Labs & Research Industry -- PAREXEL, China Cord Blood, ICON, and PRA ... - PR Newswire (press release) www.prnewswire.com - July 20 at 6:26 AM

PAREXEL International (NASDAQ:PRXL) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

PAREXEL International (NASDAQ:PRXL) Income Statement, Balance Sheet and Cash Flow Statement

PAREXEL International (NASDAQ PRXL) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff